Inozyme Pharma, Inc.
INZY
$1.62
$0.4133.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.68% | 4.23% | 3.17% | -5.70% | -6.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.12% | 40.44% | 33.07% | 18.63% | 8.11% |
| Operating Income | -40.12% | -40.44% | -33.07% | -18.63% | -8.11% |
| Income Before Tax | -43.35% | -41.55% | -30.42% | -14.10% | -6.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.35% | -41.55% | -30.42% | -14.10% | -6.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.35% | -41.55% | -30.42% | -14.10% | -6.13% |
| EBIT | -40.12% | -40.44% | -33.07% | -18.63% | -8.11% |
| EBITDA | -40.70% | -40.98% | -33.48% | -18.79% | -8.07% |
| EPS Basic | -17.11% | -6.07% | 5.72% | 13.55% | 26.84% |
| Normalized Basic EPS | -19.89% | -8.45% | 3.72% | 11.78% | 28.54% |
| EPS Diluted | -17.15% | -6.13% | 5.64% | 13.39% | 26.71% |
| Normalized Diluted EPS | -19.89% | -8.45% | 3.72% | 11.78% | 28.54% |
| Average Basic Shares Outstanding | 21.25% | 31.59% | 37.68% | 31.84% | 37.38% |
| Average Diluted Shares Outstanding | 21.25% | 31.59% | 37.68% | 31.84% | 37.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |